Haleon (HLN) Total Debt (2021 - 2026)

Haleon's (HLN) quarterly Total Debt came in at -$8.4 billion in Q2 2026, up 9.2% on a QoQ basis from -$9.3 billion in Q4 2025.

Haleon (HLN) Total Debt (2021 - 2026) Analysis & Trends

Haleon (HLN) has 6 years of Total Debt data on file, last reported at -$8.4 billion in Q2 2026.

Quarterly Total Debt changed N/A year-over-year to -$8.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$8.4 billion (changed N/A YoY) and the FY2025 annual result came in at -$9.2 billion, down 171.28% from the prior year.
Total Debt advanced to -$8.4 billion in Q2 2026, from -$9.3 billion in the prior quarter.
In the past five years, Total Debt ranged from a high of $13.0 billion in Q4 2024 to a low of -$12.5 billion in Q2 2022.
A 5-year average of -$1.3 billion and a median of -$8.0 billion in 2026 frame the typical range for Total Debt.
Annual changes were most pronounced in 2022 — Total Debt soared 5372.31% — and 2025, when it plunged 171.51%.
Tracing HLN's Total Debt over 5 years: stood at $12.2 billion in 2022, then slipped by 4.16% to $11.7 billion in 2023, then advanced by 10.75% to $13.0 billion in 2024, then slumped by 171.51% to -$9.3 billion in 2025, then increased by 9.2% to -$8.4 billion in 2026.
The last three Total Debt figures came in at -$8.4 billion (Q2 2026), -$9.3 billion (Q4 2025), and $13.0 billion (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-5.81 Bn
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	16.59 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	9.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	31.47 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	-
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	13.35 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	-
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	3.92 Bn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	760.00 Mn
10	Alkermes	8.02 Bn	7.37 Bn	397.90 Mn	1.50 Bn

Download Data